Valuation: AstraZeneca PLC

Market Cap 25TCr 22TCr 21TCr 19TCr 36TCr 24,39200Cr 36TCr 2,52300Cr 98TCr 12,43600Cr 95TCr 93TCr 40,37400Cr P/E 2026 *
20.9x
P/E 2027 * 18.2x
Enterprise Value 27TCr 24TCr 23TCr 21TCr 39TCr 26,28100Cr 39TCr 2,71800Cr 1,05400Cr 13,39900Cr 1,02800Cr 1,00600Cr 43,50100Cr EV / Sales 2026 *
4.34x
EV / Sales 2027 * 3.97x
Free-Float
96.62%
Yield 2026 *
2.04%
Yield 2027 * 2.16%
1 day+0.75%
Current month+77.38%
Current year+79.01%
Current year 89.04
Extreme 89.04
166.25
1 year 72.9
Extreme 72.895
166.25
3 years 60.47
Extreme 60.47
166.25
5 years 52.65
Extreme 52.65
166.25
10 years 25.55
Extreme 25.55
166.25
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%+0.27% - - 26TCr
Average +0.75%
Weighted average by Cap. +0.75%

Financials

2026 *2027 *
Net sales 6.32TCr 5.55TCr 5.23TCr 4.78TCr 8.93TCr 6,06000Cr 9.01TCr 63TCr 24TCr 3,09000Cr 24TCr 23TCr 10,03100Cr 6.7TCr 5.89TCr 5.55TCr 5.07TCr 9.48TCr 6,42900Cr 9.56TCr 67TCr 26TCr 3,27800Cr 25TCr 25TCr 10,64200Cr
Net income 1.2TCr 1.06TCr 997.08Cr 911.36Cr 1.7TCr 1,15600Cr 1.72TCr 12TCr 4.63TCr 59TCr 4.52TCr 4.42TCr 1,91300Cr 1.38TCr 1.21TCr 1.14TCr 1.04TCr 1.95TCr 1,32100Cr 1.97TCr 14TCr 5.3TCr 67TCr 5.17TCr 5.06TCr 2,18700Cr
Net Debt 1.97TCr 1.73TCr 1.63TCr 1.49TCr 2.79TCr 1,89000Cr 2.81TCr 20TCr 7.58TCr 96TCr 7.39TCr 7.23TCr 3,12800Cr 1.19TCr 1.05TCr 987.74Cr 902.83Cr 1.69TCr 1,14500Cr 1.7TCr 12TCr 4.59TCr 58TCr 4.48TCr 4.38TCr 1,89500Cr
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
24/26/24 $164.56 +0.75% 30,19,774
23/26/23 $163.33 -2.99% 23,61,340
22/26/22 $168.37 +0.16% 23,06,261
21/26/21 $168.10 +1.22% 29,37,798
18/26/18 $166.08 -0.04% 30,60,378
Trader
Investor
Global
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise